“By inserting a durable, functioning gene into a safe-harbor site in T cells using lipid nanoparticle-delivered RNA, our technology is designed to create safer, re-dosable genetic medicines that are accessible to many more patients than current cumbersome and complex CAR T approaches,” said Matthew Stanton, PhD, Chief Executive Officer and Board Director of Typewriter Therapeutics. “This financing enables us to build on the proof-of-concept we have established in humanized mouse models and establish our first in vivo CAR T development candidate.”